Skip to content

Research at St Andrews

Managing malaria in tuberculosis patients on fluoroquinolone-containing regimens: assessing the risk of QT prolongation.

Research output: Contribution to journalReview article

DOI

Abstract

The role of fluoroquinolones (FQs) in the management of drug-susceptible and drug-resistant tuberculosis (TB) is under investigation. They are currently being used off-licence to treat TB patients who develop hepatotoxicity on standard therapy, and in patients with drug-resistant disease. Prolongation of ventricular repolarisation, recorded as lengthening of the QT interval on an electrocardiogram, is a recognised adverse effect associated with FQs. Significant prolongation of the QT interval may precipitate torsades de pointe, a potentially fatal tachyarrhythmia. Currently licensed FQs are considered safe, and there are very few reports of associated arrhythmias, but most labels contraindicate concomitant administration of other agents that prolong QT. In many high TB burden countries, malaria is also endemic. Many antimalarials, and possibly malaria infection itself, may prolong QT; under current licence, co-administration of FQs with these antimalarials is contraindicated due to potential risk of additive QT prolongation. This poses significant challenges in planning future policy on FQ use for first-line anti-tuberculosis treatment; the duration of TB treatment makes concomitant malaria treatment inevitable, and options without FQ contraindications are limited. Furthermore, malaria diagnosis is often poor and access to treatment uncontrolled, with many patients buying 'over-the-counter' and/or 'traditional' remedies; concomitant use with anti-tuberculosis treatment is thus likely to be unregulated. Drug interaction studies are urgently required to assess the safety of managing patients with TB and malaria within endemic, resource-poor settings where programmatic management and low-cost monitoring are essential for effective implementation of public health strategies.
Close

Details

Original languageEnglish
Pages (from-to)144-149
Number of pages6
JournalInternational Journal of Tuberculosis and Lung Disease
Volume16
Issue number2
DOIs
Publication statusPublished - Feb 2012

    Research areas

  • tuberculosis, malaria, qt interval, drug toxicity, clinical trials, therapeutics

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Mimicking in-vivo exposures to drug combinations in-vitro: anti-tuberculosis drugs in lung lesions and the hollow fiber model of infection

    Kloprogge, F., Hammond, R., Kipper, K., Gillespie, S. H. & Della Pasqua, O., 13 Sep 2019, In : Scientific Reports. 9, 8 p., 13228.

    Research output: Contribution to journalArticle

  2. A tuberculosis molecular bacterial load assay (TB-MBLA)

    Sabiiti, W., Mtafya, B. A., Alferes De Lima, D., Dombay, E., Baron, V. O., Azam, K., Orascova, K., Sloan, D. J. & Gillespie, S. H., 6 Sep 2019, (Accepted/In press) In : Journal of Visualized Experiments.

    Research output: Contribution to journalArticle

  3. Can phenotypic data complement our understanding of antimycobacterial effects for drug combinations?

    Kloprogge, F., Hammond, R., Copas, A., Gillespie, S. H. & Della Pasqua, O., 25 Aug 2019, In : Journal of Antimicrobial Chemotherapy. Advance article, 7 p.

    Research output: Contribution to journalArticle

  4. Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status

    Tweed, C. D., Crook, A. M., Dawson, R., Diacon, A. H., McHugh, T. D., Mendel, C. M., Meredith, S. K., Mohapi, L., Murphy, M. E., Nunn, A. J., Phillips, P. P. J., Singh, K. P., Spigelman, M. & Gillespie, S. H., 14 Aug 2019, In : BMC Pulmonary Medicine. 19, 9 p., 152.

    Research output: Contribution to journalArticle

  5. Model-based relationship between the molecular bacterial load assay and time-to-positivity in liquid culture

    Svensson, R. J., Sabiiti, W., Kibiki, G. S., Ntinginya, N. E., Bhatt, N., Davies, G., Gillespie, S. H. & Simonsson, U. S. H., 29 Jul 2019, In : Antimicrobial Agents and Chemotherapy. Early

    Research output: Contribution to journalArticle

Related by journal

  1. International Journal of Tuberculosis and Lung Disease (Journal)

    Stephen Henry Gillespie (Editor)
    2011

    Activity: Publication peer-review and editorial work typesEditor of research journal

Related by journal

  1. Equitable tuberculosis care in the North West of England: analysis of tuberculosis cohort review data

    MacPherson, P., Squire, S. B., Cleary, P., Davies, S., Wake, C., Dee, K., Walker, J., Farrow, S., McMaster, P., Woodhead, M., Sloan, D. J. & North West TB Audit Steering Committee, 1 Jun 2016, In : International Journal of Tuberculosis and Lung Disease. 20, 6, p. 778-785 8 p.

    Research output: Contribution to journalArticle

  2. Optimising molecular diagnostic capacity for effective control of tuberculosis in high-burden settings

    Sabiiti, W., Mtafya, B., Kuchaka, D., Azam, K., Viegas, S., Mdolo, A., Farmer, E., Khonga, M., Evangelopoulos, D., Honeyborne, I., Rachow, A., Heinrich, N., Ntinginya, N. E., Bhatt, N., Davies, G. R., Jani, I. V., McHugh, T. D., Kibiki, G., Hoelscher, M., Gillespie, S. H. & 1 othersPANBIOME (Pan-African Biomarker Expansion Programme) consortium, 1 Aug 2016, In : International Journal of Tuberculosis and Lung Disease. 20, 8, p. 1004-1009

    Research output: Contribution to journalArticle

  3. Tuberculosis in the time of Ebola: Obstacles and opportunities

    Sloan, D. J. & O'Dempsey, T. J., 1 Nov 2015, In : International Journal of Tuberculosis and Lung Disease. 19, 11, p. 1269 1 p.

    Research output: Contribution to journalEditorial

  4. Vitamin D deficiency in Malawian adults with pulmonary tuberculosis: risk factors and treatment outcomes

    Sloan, D. J., Mwandumba, H. C., Kamdolozi, M., Shani, D., Chisale, B., Dutton, J., Khoo, S. H., Allain, T. J. & Davies, G. R., 1 Aug 2015, In : International Journal of Tuberculosis and Lung Disease. 19, 8, p. 904-911 8 p.

    Research output: Contribution to journalArticle

ID: 16659079